Navigation Links
A tricky tumor virus
Date:1/17/2008

Epstein-Barr virus (EBV) is a human-pathogenic virus which belongs to the herpes virus family. Almost every adult carries EBV inside. With an infestation rate of more than 90 %, EBV is one of the most successful human viruses. Its viral genome consists of double-stranded DNA, and it is one of the few known viruses which cause cancer in humans under certain circumstances. EBV-associated cancers include lymphomas (cancer of the lymph nodes), nasopharyngeal carcinoma and gastric cancer.

A protein encoded by the virus, the latent membrane protein 1 (LMP1), is required for the uncontrolled proliferation of EBV-infected cells and, thus, the formation of cancer. Arnd Kieser and his team are studying the molecular mode of action of this EBV protein. LMP1 is a membrane-bound oncoprotein that binds certain signal molecules of its host cell and thereby critically contributes to the oncogenic transformation of the cells. One of these signal proteins is the factor TRADD. TRADD stands for TNF-receptor 1-associated death domain protein. The scientists used TRADD knockout cell lines which they had established by removing the TRADD gene from the genome of human B-cells in order to demonstrate that TRADD is an essential factor for LMP1 function. They found that in the absence of TRADD, LMP1 can no longer activate a cellular communication (also called: signal transduction) pathway which is crucial for cell transformation. However, TRADD's normal function within the cell includes the induction of programmed cell death which would be fatal for the virus. In fact, the scientists made the surprising observation that TRADD can no longer induce apoptosis if it is activated by the viral protein LMP1.

How does Epstein-Barr virus manage to switch off the apoptosis function of TRADD? Kieser and his colleagues discovered that the LMP1 protein possesses a unique TRADD binding domain which dictates an unusual TRADD interaction and prevents TRADD from transmitting cell death signals. Thus, LMP1 masks the apoptotic activity of TRADD. This viral TRADD-binding domain consists of the 16 carboxyterminal amino acids of the LMP1 protein and can be transplanted to cellular receptor proteins where it shows the same effects.

Hence, Epstein-Barr virus has found a unique molecular way to extinguish an undesired property of a cellular protein in order to adapt this protein to its own needs. This finding might also be the basis for a new therapeutic approach. Arnd Kieser explains: Since the specific structure of the LMP1-TRADD interaction is most likely restricted to EBV-infected cells, it might serve as a target structure to develop specific inhibitors which interrupt the transforming signal cascade of the LMP1 oncogene.


'/>"/>

Contact: Dr. Arnd Kieser
a.kieser@helmholtz-muenchen.de
0049-897-099-535
GSF - National Research Center for Environment and Health
Source:Eurekalert

Related medicine news :

1. Findings point to molecular Achilles heel for half of breast cancer tumors
2. Transplant Drug Shrinks Tumors in Women With Rare Lung Disease
3. High-energy ultrasound sharpens view of liver tumors
4. Forever young: Differentiation blocked in tumor stem cells
5. Some Immature Brain Cells May Promote Tumors
6. Hormone may be new drug target for preventing lymphedema, tumor spread
7. Area Around Breast Tumor May Predict Cancers Spread
8. Microchip Spots Stray Tumor Cells in the Bloodstream
9. Microchip-based device can detect rare tumor cells in bloodstream
10. Even Tiny Breast Tumors May Need Aggressive Treatment
11. Even tiny breast tumors can be aggressive and may require maximum therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, ... clients already in the state and in nearby New Hampshire, Massachusetts and Canada, ...
(Date:2/23/2017)... ... , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located ... 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier this ... and dentists who have earned high ratings and superior patient reviews from multiple credible ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... announced today that it will soon begin franchising throughout the U.S. starting this ... to help bring the practice of meditation mainstream. Current Meditation will be the ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
(Date:2/23/2017)... ... ... Curemark, LLC announced today that the Blüm Study, a Phase 3 clinical ... Autism, is now enrolling at three new sites. These new sites are in addition ... “There are currently no approved drugs that address the core symptoms of autism,” said ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... Feb. 23, 2017 Regulus Therapeutics Inc ... and development of innovative medicines targeting microRNAs, today announced ... financial results on Thursday, March 2, 2017 after the ... call and webcast on March 2, 2017 at 5:00 ... year 2016 financial results and provide a general business ...
(Date:2/23/2017)... PUNE, India , February 23, 2017 ... "Diagnostic Imaging Market by Product (X-ray Imaging Digital, Analog), ... PET)), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, ... MarketsandMarkets, the report studies the global market over the ... expected to reach ~USD 36.43 Billion by 2021, at ...
Breaking Medicine Technology: